Jinghua Pharmaceutical Group Valuation

Is 002349 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 002349 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 002349 (CN¥8.04) is trading above our estimate of fair value (CN¥5.77)

Significantly Below Fair Value: 002349 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 002349?

Key metric: As 002349 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 002349. This is calculated by dividing 002349's market cap by their current earnings.
What is 002349's PE Ratio?
PE Ratio	30.2x
Earnings	CN¥216.58m
Market Cap	CN¥6.33b

002349 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3.7x
Enterprise Value/EBITDA	17x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 002349's PE Ratio compare to its peers?

The above table shows the PE ratio for 002349 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	36.8x
301211 Hubei Biocause Heilen Pharmaceutical	55.6x	n/a	CN¥5.9b
000915 Shandong Wit Dyne HealthLtd	12.5x	16.5%	CN¥6.0b
301263 Guangdong Taienkang Pharmaceutical	45x	37.7%	CN¥6.0b
002390 Guizhou Xinbang Pharmaceutical	34x	n/a	CN¥7.1b
002349 Jinghua Pharmaceutical Group	30.2x	n/a	CN¥6.3b

Price-To-Earnings vs Peers: 002349 is good value based on its Price-To-Earnings Ratio (30.2x) compared to the peer average (36.8x).

Price to Earnings Ratio vs Industry

How does 002349's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap

No more companies available in this PE range

0 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 002349 is expensive based on its Price-To-Earnings Ratio (30.2x) compared to the CN Pharmaceuticals industry average (29.9x).

Price to Earnings Ratio vs Fair Ratio

What is 002349's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

002349 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	30.2x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 002349's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Sichuan Kelun Pharmaceutical

CN¥47.5b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥31.84

-3.9%

14.4%

Dong-E-E-JiaoLtd

CN¥37.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥58.44

-2.0%

18.4%

China Resources Double-Crane PharmaceuticalLtd

CN¥22.3b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥21.72

-1.2%

18.8%